skip to Main Content
Proudly Introducing the Dos Santos Team!
Dr. Mark Bentum

Stem cell therapy holds immense promise for the treatment of patients with diabetes mellitus. Dr. Mark Bentum research is based on the ability of human embryonic stem cells to differentiate into islet cells and define the developmental stages and transcription factors involved in this process. However, the clinical applications of human embryonic stem cells are limited by ethical concerns, as well as the potential for teratoma formation. As a consequence, alternative forms of stem cell therapies, such as induced pluripotent stem cells, umbilical cord stem cells and bone marrow-derived mesenchymal stem cells, have become an area of intense study. Recent advances in stem cell therapy may turn this into a realistic treatment for diabetes in the near future. Dr. Mark Bentum with the Stem cell research group is actively pioneering new drugs that are being developed at a rapid pace, and the last few years have seen several new classes of compounds for the treatment of diabetes e.g. glucagon-like peptide (GLP-1) mimetics, dipeptidyl-peptidase-4 (DPP-4) inhibitors, sodium glucose transporter-2 (SGLT2) inhibitors. Dr. Mark Bentum is also actively involved in the new surgical treatments that has also become increasingly available and advocated as effective therapies for diabetes. Gastric restriction surgery, gastric bypass surgery, simultaneous pancreas-kidney transplantation, pancreatic and islet transplantation have all been introduced in recent years

Research Members

Back To Top